The global intragastric balloon market is expected to grow at CAGR 9.1% during the forecast period, 2019-2026.
Gastric balloon is a medical device that is used in an endoscopic intragastrical procedure, where the inflated silicone balloon is inserted in the stomach and is retained there for 6–12 months. This is widely known as weight loss balloon that is designed to help individuals to eat less and feel full sooner while eating. This makes less room for food and helps the body to adapt to healthy portions. This procedure is non-surgical, non-invasive, and requires no-incision. However, this procedure is not permanent and helps individual to lose up to three times the weight when compared to diet alone. Apart from weight loss it has many health benefits as it helps in improving diabetes, maintains cardiac health, and improves other bone-related issues.
Rising demand for minimally invasive surgical procedures will significantly drive intragastric balloon market growth during the forecast period. Reduction in post-operative trauma and complications with use of non-surgical intragastric balloons is the major growth driver. Reduced hospital stays, and no blood loss are other advantages associated with use of advanced intragastric balloon across the forecast timeframe.
Rising prevalence of obesity will enhance the market growth in the near future. Adoption of sedentary lifestyle along with unhealthy diet and alcohol abuse are the major causes of growing incidence of obesity. According to World Health Organization (WHO), in 2016, more than 1.9 billion people across the globe were overweight and about 650 million people were obese. High prevalence of obesity will lead to high adoption rate of intragastric balloon during the projected timeframe.
Rising cases of obesity increase the risk of premature death from stroke, heart disease, gallbladder disease, type 2 diabetes, and some cancers. Existence of established healthcare infrastructure tied with favorable regulatory scenario will the drive industry growth.
Developments to reduce unwanted effects such as gastric erosion, ulceration and vomiting will foster business growth. For example, new systems such as Spatz adjustable balloon and reshape duo are specially designed with antimigration properties that avoids migration and allows balloon volume alteration. Such developments will boost intragastric balloon industry growth during the projected timeframe.
The market research study on “Intragastric Balloon Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers a detailed outlook, strategic recommendations, and insightful viewpoints on the global Intragastric balloon market. The report also analyzes the key players operating in intragastric balloon market and identifies the key strategies deployed by them along with the market share of leading players.
The global intragastric balloon market is segmented as below:
Intragastric Balloon Market By Product
Intragastric Balloon Market By Filling Material
Intragastric Balloon Market By End User
Intragastric Balloon Market By Geography
The global Intragastric Balloon market is segmented by product, filling material, end user.
By product the global intragastric balloon market is segmented into orbera (Single), reshape (Dual) and Obalon (triple) intragastric balloons. The orbera (single) gastric balloon held the largest share of the market. Additionally, the segment is also expected to grow at the fastest during the forecast period owing to better benefits offered as compared to the dual and triple gastric balloon, also the implantation of a single balloon causes less discomfort, leading to its rising preference. As most of the population has a BMI index of 27-45 kg / m 2 the demand for the orbera (single) gastric balloon is high. According to a study conducted by soma bariatric in 2016 there were about 320,000 patients with orbera (single) intragastric balloon globally.
By technology the global intragastric balloon market is segmented into Saline-filled and gas-filled. Saline filled intragastric balloons accounted for major revenue share owing to its ability to reduce weight more efficiently and quick recognition of silicone balloon deflation due to methylene blue dye and will favor adoption rate. Saline-filled intragastric balloon treatment is used to lose about one-quarter of body weight.
By end user the intragastric balloon pump market is segmented into hospitals, ambulatory surgical centers and clinics. With hospitals sharing the highest market share during the forecast period due to the rising number of obesity cases across the globe. Furthermore, government policies for the implementation of high-quality patient care are attracting a large number of patients in hospitals to seek treatments. Growing disease burden and increasing healthcare investments have fueled the growth of this segment.
Geographical the intragastric balloon market is segmented into five regions: America, Europe, Asia Pacific, Latin America and Middle East and Africa.
North America leads the market owing to the highest obesity rate in the world. Presence of well-known healthcare infrastructure coupled with favorable governing scenario should drive industry growth. According to the Organization for Economic Co-operation and Development (OECD), about 47% of the total population suffer from obesity in 2017.
Asia Pacific market will have an abrupt growth owing to the rise in the medical tourism, lower cost of healthcare, and rise in the development of healthcare infrastructure in developing countries like India, China, Japan. According to a study published in the International Journal of Community Medicine and Public Health, more than 100 million people in India suffer from obesity. Furthermore, rising medical tourism to treat obesity due to important improvement in quality of healthcare amenities and lower cost is expected to favor industry growth.
Europe is expected to expand at a substantial growth and will contribute to the global intragastric balloons market value exhibiting a robust opportunity. Continuously increasing demand for the new and better medical devices and increasing government support have supported the growth of the market.
On the other hand, LAMEA holds the least share in the global intragastric balloons market but possess a huge opportunity for the market growth in near future owing to the increasing spending of the people, and developing economies.
The major players are Allurion Technologies Inc. (U.S.), Apollo Endosurgery, Inc (U.S.), Districlass Medical (France), Helioscopie Medical Implants (France), Silimed (Brazil), Lexel S.R.L (Argentina), Medsil (Russia), Obalon Therapeutics (U.S.), ReShape Lifesciences (U.S.), Spatz3 (U.S.)